Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
|Videos|December 8, 2022
Dr. Antonarakis on the frequency of genetic testing for prostate cancer in urology clinics
Author(s)Urology Times staff
Advertisement
Emmanuel S. Antonarakis, MD, discusses the frequency of genetic testing in urology clinics for the management of patients with prostate cancer. He is associate director for Translational Research at the University of Minnesota Medical School Masonic Cancer Center, as well as the Clark Endowed Professor of Medicine and director of Genitourinary Oncology in the Department of Medicine’s Division of Hematology, Oncology, and Transplantation.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Urology Times
1
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
2
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
3
FDA updates in urology: September 2026
4
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
5